Simponi (Rheumatoid Arthritis) Forecast and Market Analysis


#157665

38pages

GlobalData

$ 3495

In Stock


Simponi (Rheumatoid Arthritis) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Simponi (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizers Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lillys anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZs SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market. Johnson & Johnsons Simponi (golimumab) is a subcutaneous fully human IgG1 mAb specific for TNF-alpha. It inhibits TNF-alpha activity, thereby modulating immune activity in RA patients and thus blocking inflammatory activity of TNF-alpha. Simponi is prescribed to patients with moderate to severe active RA who have failed another anti-TNF agent or had unsatisfactory response with MTX. It is also prescribed for other immunological indications including ankylosing spondylitis and psoriatic arthritis.

Scope

  • Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Simponi (golimumab) including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Simponi (golimumab) for the top eight countries from 2011 to 2022.
  • Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Simponi (golimumab) performance
  • Obtain sales forecast for Simponi (golimumab) from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)